Attached files
file | filename |
---|---|
EX-21 - EXHIBIT 21 - Cardiff Oncology, Inc. | exhibit21q42015.htm |
EX-31.2 - EXHIBIT 31.2 - Cardiff Oncology, Inc. | exhibit312q42015.htm |
EX-32.1 - EXHIBIT 32.1 - Cardiff Oncology, Inc. | exhibit321q42015.htm |
EX-31.1 - EXHIBIT 31.1 - Cardiff Oncology, Inc. | exhibit311q42015.htm |
EX-10.32 - EXHIBIT 10.32 - Cardiff Oncology, Inc. | exhibit1032q42015.htm |
EX-10.30 - EXHIBIT 10.30 - Cardiff Oncology, Inc. | exhibit1030q42015.htm |
EX-10.28 - EXHIBIT 10.28 - Cardiff Oncology, Inc. | exhibit1028q42015.htm |
EX-10.31 - EXHIBIT 10.31 - Cardiff Oncology, Inc. | exhibit1031q42015.htm |
EX-10.29 - EXHIBIT 10.29 - Cardiff Oncology, Inc. | exhibit1029q42015.htm |
10-K - 10-K - Cardiff Oncology, Inc. | trov-123115x10k.htm |
EX-32.2 - EXHIBIT 32.2 - Cardiff Oncology, Inc. | exhibit322q42015.htm |
Exhibit 21
Consent of Independent Registered Public Accounting Firm
Trovagene, Inc.
San Diego, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-208010) and Form S-8 (Nos. 333-205424 and 333-190415) of Trovagene, Inc. of our reports dated March 10, 2016, relating to the consolidated financial statements, and the effectiveness of Trovagene, Inc.’s internal control over financial reporting, which appear in this Form 10-K.
/s/ BDO USA, LLP
San Diego, California
March 10, 2016